• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用isatuximab、泊马度胺和地塞米松有效治疗难治性单克隆丙种球蛋白病相关纯红细胞再生障碍性贫血。

Effective treatment of refractory monoclonal gammopathy-associated pure red cell aplasia with isatuximab, pomalidomide and dexamethasone.

作者信息

Michel Christian Sebastian, Fehr Eva Marie, Nolte Hildegard, Beck Joachim, Kreft Andreas, Rauschkolb-Olk Katharina Theresa, Jacobi Bjoern, Theobald Matthias, Munder Markus

机构信息

Department of Hematology and Medical Oncology University Medical Center of the Johannes Gutenberg University Mainz Germany.

Department of Pathology University Medical Center of the Johannes Gutenberg University Mainz Germany.

出版信息

EJHaem. 2024 Jun 17;5(4):838-841. doi: 10.1002/jha2.964. eCollection 2024 Aug.

DOI:10.1002/jha2.964
PMID:39157595
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11327726/
Abstract

Monoclonal gammopathy-associated pure red cell aplasia (MG-PRCA) is characterized by the absence or pronounced hypoplasia of erythroid precursors in the bone marrow, causing reticulocytopenia and a normocytic, normochromic anaemia in a patient with a monoclonal plasma cell dyscrasia. We report here on the successful treatment of MG-PRCA with isatuximab, pomalidomide, and dexamethasone after multiple lines of immunosuppressive and anti-plasma cell-directed treatments.

摘要

单克隆丙种球蛋白病相关纯红细胞再生障碍性贫血（MG-PRCA）的特征是骨髓中红系前体细胞缺失或显著发育不全，导致单克隆浆细胞异常增生患者出现网织红细胞减少和正细胞正色素性贫血。我们在此报告，在经过多线免疫抑制和抗浆细胞定向治疗后，使用isatuximab、泊马度胺和地塞米松成功治疗MG-PRCA的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5226/11327726/be49467da9e1/JHA2-5-838-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5226/11327726/b691dadc1aed/JHA2-5-838-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5226/11327726/be49467da9e1/JHA2-5-838-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5226/11327726/b691dadc1aed/JHA2-5-838-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5226/11327726/be49467da9e1/JHA2-5-838-g001.jpg

相似文献

1
Effective treatment of refractory monoclonal gammopathy-associated pure red cell aplasia with isatuximab, pomalidomide and dexamethasone.使用isatuximab、泊马度胺和地塞米松有效治疗难治性单克隆丙种球蛋白病相关纯红细胞再生障碍性贫血。
EJHaem. 2024 Jun 17;5(4):838-841. doi: 10.1002/jha2.964. eCollection 2024 Aug.
2
Monoclonal gammopathy-associated pure red cell aplasia.单克隆丙种球蛋白病相关的纯红细胞再生障碍性贫血。
Br J Haematol. 2016 Jun;173(6):876-83. doi: 10.1111/bjh.14012. Epub 2016 Mar 21.
3
Pure Red Cell Aplasia Associated with Monoclonal Gammopathy of Undetermined Significance and Literature Review.意义未明的单克隆丙种球蛋白病相关纯红细胞再生障碍性贫血及文献综述
Clin Lab. 2017 Feb 1;63(2):373-378. doi: 10.7754/Clin.Lab.2016.160730.
4
Good treatment-free survival of monoclonal gammopathy of undetermined significance associated pure red cell aplasia after bortezomib plus dexamethasone.硼替佐米联合地塞米松治疗意义未明的单克隆丙种球蛋白病相关纯红细胞再生障碍性贫血后获得良好的无治疗生存期。
Blood Cells Mol Dis. 2021 Jul;89:102573. doi: 10.1016/j.bcmd.2021.102573. Epub 2021 Apr 27.
5
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
6
The co-existence of pure red cell aplasia and autoimmune haemolytic anaemia in a child with malignant lymphoma.一名患有恶性淋巴瘤的儿童同时存在纯红细胞再生障碍和自身免疫性溶血性贫血。
Malays J Med Sci. 2005 Jul;12(2):56-9.
7
Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib.伴有 T 细胞大颗粒淋巴细胞白血病的难治性纯红细胞再生障碍性贫血经芦可替尼治疗。
Ann Hematol. 2024 Aug;103(8):3239-3242. doi: 10.1007/s00277-024-05856-z. Epub 2024 Jun 27.
8
[Diagnosis and management of pure red cell aplasia].[纯红细胞再生障碍性贫血的诊断与管理]
Rinsho Ketsueki. 2021;62(8):931-937. doi: 10.11406/rinketsu.62.931.
9
Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment.伴有20号染色体长臂缺失（Del(20q)）的纯红细胞再生障碍性贫血对免疫抑制治疗敏感。
Case Rep Hematol. 2020 Jan 20;2020:1262038. doi: 10.1155/2020/1262038. eCollection 2020.
10
Use of IV immunoglobulin to treat steroid resistant, immune checkpoint inhibitor-induced pure red cell aplasia: A case report.静脉注射免疫球蛋白治疗类固醇抵抗性、免疫检查点抑制剂诱导的纯红细胞再生障碍性贫血：一例报告。
EJHaem. 2024 Jun 16;5(4):825-828. doi: 10.1002/jha2.937. eCollection 2024 Aug.

引用本文的文献

1
Anti-plasma cell therapy in patients with monoclonal gammopathy-associated refractory pure red cell aplasia: A report of three cases and literature review.单克隆丙种球蛋白病相关难治性纯红细胞再生障碍性贫血患者的抗浆细胞治疗：三例报告及文献综述
Ann Hematol. 2025 Aug 21. doi: 10.1007/s00277-025-06565-x.
2
[Clonal diseases in the border zone rheumatology/hematology].[交界区风湿病/血液学中的克隆性疾病]
Z Rheumatol. 2025 Jul 9. doi: 10.1007/s00393-025-01678-0.
3
Rare case of pure red cell aplasia secondary to smoldering multiple myeloma successfully treated with daratumumab - case report and review of the literature.

本文引用的文献

1
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.来那度胺耐药、蛋白酶体抑制剂暴露的多发性骨髓瘤患者中口服伊沙佐米-地塞米松与口服泊马度胺-地塞米松的对比：一项随机 2 期试验。
Blood Cancer J. 2022 Jan 24;12(1):9. doi: 10.1038/s41408-021-00593-2.
2
Good treatment-free survival of monoclonal gammopathy of undetermined significance associated pure red cell aplasia after bortezomib plus dexamethasone.硼替佐米联合地塞米松治疗意义未明的单克隆丙种球蛋白病相关纯红细胞再生障碍性贫血后获得良好的无治疗生存期。
Blood Cells Mol Dis. 2021 Jul;89:102573. doi: 10.1016/j.bcmd.2021.102573. Epub 2021 Apr 27.
3
达雷妥尤单抗成功治疗冒烟型多发性骨髓瘤继发纯红细胞再生障碍性贫血的罕见病例——病例报告及文献综述
Ann Hematol. 2025 Mar;104(3):2027-2034. doi: 10.1007/s00277-025-06218-z. Epub 2025 Feb 19.
Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma.
血清促红细胞生成素水平与多发性骨髓瘤致肾功能损害患者肾脏逆转的相关性。
Cancer Med. 2020 Jun;9(12):4460-4466. doi: 10.1002/cam4.3050. Epub 2020 Apr 20.
4
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
5
Acquired red cell aplasia associated with monoclonal gammopathy of undetermined significance.获得性红细胞再生障碍伴意义未明的单克隆丙种球蛋白病。
Leuk Lymphoma. 2019 Sep;60(9):2337-2339. doi: 10.1080/10428194.2019.1574007. Epub 2019 Feb 3.
6
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.肾脏意义单克隆丙种球蛋白病的评估：国际肾脏病和单克隆丙种球蛋白病研究小组的共识报告。
Nat Rev Nephrol. 2019 Jan;15(1):45-59. doi: 10.1038/s41581-018-0077-4.
7
Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications.有临床意义的单克隆丙种球蛋白病：一个具有治疗意义的新概念。
Blood. 2018 Oct 4;132(14):1478-1485. doi: 10.1182/blood-2018-04-839480. Epub 2018 Jul 16.
8
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
9
Monoclonal gammopathy-associated pure red cell aplasia.单克隆丙种球蛋白病相关的纯红细胞再生障碍性贫血。
Br J Haematol. 2016 Jun;173(6):876-83. doi: 10.1111/bjh.14012. Epub 2016 Mar 21.
10
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.卡非佐米和地塞米松与硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者的比较（ENDEAVOR）：一项随机、3 期、开放标签、多中心研究。
Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.